Novo Nordisk A/S-BNONOF
13F holders, Q2 2024 (June 30)3holders
0new positions
0sold out
$144.12avg. 13F price*
At the end of Q2 2024, 3 institutions reported holding Novo Nordisk A/S-B (NONOF) in their 13F filings, unchanged from Q1 2024. 0 opened new positions and 0 sold out. The largest holders were Kennedy Capital Management LLC ($23.7M), Atlas Capital Advisors Inc. ($754K) and GAMMA Investing LLC ($38K).
- Company
- Novo Nordisk A/S-B
- CUSIP
- K72807140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 57,436 shares bought, net +57,436 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Kennedy Capital Management LLC | 0.51% | Add +53.6% | 164,577 | $23.7M |
| Atlas Capital Advisors Inc. | 0.10% | No change | 5,218 | $754K |
| GAMMA Investing LLC | 0.01% | No change | 258 | $38K |
"% of holder's portfolio" is NONOF's weight in each manager's 13F, not the share of Novo Nordisk A/S-B the manager owns.